Consolidated Statements of Operations (Unaudited) (USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Revenues:
Grants and contracts	$ 1,635,600	$ 219,575	$ 4,616,334	$ 1,409,209
Operating expenses:
Research and development	4,205,238	4,841,324	14,909,882	16,920,400
General and administrative	3,286,830	3,219,792	9,787,053	8,973,949
Total operating expenses	7,492,068	8,061,116	24,696,935	25,894,349
Loss from operations	(5,856,468)	(7,841,541)	(20,080,601)	(24,485,140)
Other income (expense):
Interest and other income	97,534	228,580	225,299	354,473
Foreign exchange gain (loss)	(15,057)	(278,940)	59,853	(330,024)
Change in value of warrant liability	1,163,030	(4,423,775)	510,919	(160,749)
Total other income (expense)	1,245,507	(4,474,135)	796,071	(136,300)
Net loss	(4,610,961)	(12,315,676)	(19,284,530)	(24,621,440)
Net loss attributable to noncontrolling interests	519,765	1,437,840	2,386,900	3,277,774
Net loss attributable to Cleveland BioLabs, Inc.	$ (4,091,196)	$ (10,877,836)	$ (16,897,630)	$ (21,343,666)
Net loss available to common stockholders per share of common stock, basic and diluted (in Dollars per share)	$ (0.09)	$ (0.30)	$ (0.38)	$ (0.60)
Weighted average number of shares used in calculating net loss per share, basic and diluted (in Shares)	45,061,274	35,879,245	44,946,340	35,761,260